Cargando…

High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19: first results of ReumaCoV Brasil registry

OBJECTIVES: To evaluate risk factors associated with unfavourable outcomes: emergency care, hospitalisation, admission to intensive care unit (ICU), mechanical ventilation and death in patients with immune-mediated rheumatic disease (IMRD) and COVID-19. METHODS: Analysis of the first 8 weeks of obse...

Descripción completa

Detalles Bibliográficos
Autores principales: Marques, Claudia Diniz Lopes, Kakehasi, Adriana Maria, Pinheiro, Marcelo Medeiros, Mota, Licia Maria Henrique, Albuquerque, Cleandro Pires, Silva, Carolina Rocha, Santos, Gabriela Porfirio Jardim, Reis-Neto, Edgard Torres, Matos, Pedro, Devide, Guilherme, Dantas, Andrea, Giorgi, Rina Dalva, Omura, Felipe, Marinho, Adriana de Oliveira, Valadares, Lilian David Azevedo, Melo, Ana Karla G, Ribeiro, Francinne Machado, Ferreira, Gilda Aparecida, Santos, Flavia Patricia de Sena, Ribeiro, Sandra Lucia Euzebio, Andrade, Nicole Pamplona Bueno, Yazbek, Michel Alexandre, de Souza, Viviane Angelina, Paiva, Eduardo S, Azevedo, Valderilio Feijo, de Freitas, Ana Beatriz Santos Bacchiega, Provenza, José Roberto, de Toledo, Ricardo Acayaba, Fontenelle, Sheilla, Carneiro, Sueli, Xavier, Ricardo, Pileggi, Gecilmara Cristina Salviato, Reis, Ana Paula Monteiro Gomides
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7844930/
https://www.ncbi.nlm.nih.gov/pubmed/33510041
http://dx.doi.org/10.1136/rmdopen-2020-001461
_version_ 1783644454974914560
author Marques, Claudia Diniz Lopes
Kakehasi, Adriana Maria
Pinheiro, Marcelo Medeiros
Mota, Licia Maria Henrique
Albuquerque, Cleandro Pires
Silva, Carolina Rocha
Santos, Gabriela Porfirio Jardim
Reis-Neto, Edgard Torres
Matos, Pedro
Devide, Guilherme
Dantas, Andrea
Giorgi, Rina Dalva
Omura, Felipe
Marinho, Adriana de Oliveira
Valadares, Lilian David Azevedo
Melo, Ana Karla G
Ribeiro, Francinne Machado
Ferreira, Gilda Aparecida
Santos, Flavia Patricia de Sena
Ribeiro, Sandra Lucia Euzebio
Andrade, Nicole Pamplona Bueno
Yazbek, Michel Alexandre
de Souza, Viviane Angelina
Paiva, Eduardo S
Azevedo, Valderilio Feijo
de Freitas, Ana Beatriz Santos Bacchiega
Provenza, José Roberto
de Toledo, Ricardo Acayaba
Fontenelle, Sheilla
Carneiro, Sueli
Xavier, Ricardo
Pileggi, Gecilmara Cristina Salviato
Reis, Ana Paula Monteiro Gomides
author_facet Marques, Claudia Diniz Lopes
Kakehasi, Adriana Maria
Pinheiro, Marcelo Medeiros
Mota, Licia Maria Henrique
Albuquerque, Cleandro Pires
Silva, Carolina Rocha
Santos, Gabriela Porfirio Jardim
Reis-Neto, Edgard Torres
Matos, Pedro
Devide, Guilherme
Dantas, Andrea
Giorgi, Rina Dalva
Omura, Felipe
Marinho, Adriana de Oliveira
Valadares, Lilian David Azevedo
Melo, Ana Karla G
Ribeiro, Francinne Machado
Ferreira, Gilda Aparecida
Santos, Flavia Patricia de Sena
Ribeiro, Sandra Lucia Euzebio
Andrade, Nicole Pamplona Bueno
Yazbek, Michel Alexandre
de Souza, Viviane Angelina
Paiva, Eduardo S
Azevedo, Valderilio Feijo
de Freitas, Ana Beatriz Santos Bacchiega
Provenza, José Roberto
de Toledo, Ricardo Acayaba
Fontenelle, Sheilla
Carneiro, Sueli
Xavier, Ricardo
Pileggi, Gecilmara Cristina Salviato
Reis, Ana Paula Monteiro Gomides
author_sort Marques, Claudia Diniz Lopes
collection PubMed
description OBJECTIVES: To evaluate risk factors associated with unfavourable outcomes: emergency care, hospitalisation, admission to intensive care unit (ICU), mechanical ventilation and death in patients with immune-mediated rheumatic disease (IMRD) and COVID-19. METHODS: Analysis of the first 8 weeks of observational multicentre prospective cohort study (ReumaCoV Brasil register). Patients with IMRD and COVID-19 according to the Ministry of Health criteria were classified as eligible for the study. RESULTS: 334 participants were enrolled, a majority of them women, with a median age of 45 years; systemic lupus erythematosus (32.9%) was the most frequent IMRD. Emergency care was required in 160 patients, 33.0% were hospitalised, 15.0% were admitted to the ICU and 10.5% underwent mechanical ventilation; 28 patients (8.4%) died. In the multivariate adjustment model for emergency care, diabetes (prevalence ratio, PR 1.38; 95% CI 1.11 to 1.73; p=0.004), kidney disease (PR 1.36; 95% CI 1.05 to 1.77; p=0.020), oral glucocorticoids (GC) (PR 1.49; 95% CI 1.21 to 1.85; p<0.001) and pulse therapy with methylprednisolone (PR 1.38; 95% CI 1.14 to 1.67; p=0.001) remained significant; for hospitalisation, age >50 years (PR 1.89; 95% CI 1.26 to 2.85; p=0.002), no use of tumour necrosis factor inhibitor (TNFi) (PR 2.51;95% CI 1.16 to 5.45; p=0.004) and methylprednisolone pulse therapy (PR 2.50; 95% CI 1.59 to 3.92; p<0.001); for ICU admission, oral GC (PR 2.24; 95% CI 1.36 to 3.71; p<0.001) and pulse therapy with methylprednisolone (PR 1.65; 95% CI 1.00 to 2.68; p<0.043); the two variables associated with death were pulse therapy with methylprednisolone or cyclophosphamide (PR 2.86; 95% CI 1.59 to 5.14; p<0.018). CONCLUSIONS: Age >50 years and immunosuppression with GC and cyclophosphamide were associated with unfavourable outcomes of COVID-19. Treatment with TNFi may have been protective, perhaps leading to the COVID-19 inflammatory process.
format Online
Article
Text
id pubmed-7844930
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-78449302021-01-29 High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19: first results of ReumaCoV Brasil registry Marques, Claudia Diniz Lopes Kakehasi, Adriana Maria Pinheiro, Marcelo Medeiros Mota, Licia Maria Henrique Albuquerque, Cleandro Pires Silva, Carolina Rocha Santos, Gabriela Porfirio Jardim Reis-Neto, Edgard Torres Matos, Pedro Devide, Guilherme Dantas, Andrea Giorgi, Rina Dalva Omura, Felipe Marinho, Adriana de Oliveira Valadares, Lilian David Azevedo Melo, Ana Karla G Ribeiro, Francinne Machado Ferreira, Gilda Aparecida Santos, Flavia Patricia de Sena Ribeiro, Sandra Lucia Euzebio Andrade, Nicole Pamplona Bueno Yazbek, Michel Alexandre de Souza, Viviane Angelina Paiva, Eduardo S Azevedo, Valderilio Feijo de Freitas, Ana Beatriz Santos Bacchiega Provenza, José Roberto de Toledo, Ricardo Acayaba Fontenelle, Sheilla Carneiro, Sueli Xavier, Ricardo Pileggi, Gecilmara Cristina Salviato Reis, Ana Paula Monteiro Gomides RMD Open Infections OBJECTIVES: To evaluate risk factors associated with unfavourable outcomes: emergency care, hospitalisation, admission to intensive care unit (ICU), mechanical ventilation and death in patients with immune-mediated rheumatic disease (IMRD) and COVID-19. METHODS: Analysis of the first 8 weeks of observational multicentre prospective cohort study (ReumaCoV Brasil register). Patients with IMRD and COVID-19 according to the Ministry of Health criteria were classified as eligible for the study. RESULTS: 334 participants were enrolled, a majority of them women, with a median age of 45 years; systemic lupus erythematosus (32.9%) was the most frequent IMRD. Emergency care was required in 160 patients, 33.0% were hospitalised, 15.0% were admitted to the ICU and 10.5% underwent mechanical ventilation; 28 patients (8.4%) died. In the multivariate adjustment model for emergency care, diabetes (prevalence ratio, PR 1.38; 95% CI 1.11 to 1.73; p=0.004), kidney disease (PR 1.36; 95% CI 1.05 to 1.77; p=0.020), oral glucocorticoids (GC) (PR 1.49; 95% CI 1.21 to 1.85; p<0.001) and pulse therapy with methylprednisolone (PR 1.38; 95% CI 1.14 to 1.67; p=0.001) remained significant; for hospitalisation, age >50 years (PR 1.89; 95% CI 1.26 to 2.85; p=0.002), no use of tumour necrosis factor inhibitor (TNFi) (PR 2.51;95% CI 1.16 to 5.45; p=0.004) and methylprednisolone pulse therapy (PR 2.50; 95% CI 1.59 to 3.92; p<0.001); for ICU admission, oral GC (PR 2.24; 95% CI 1.36 to 3.71; p<0.001) and pulse therapy with methylprednisolone (PR 1.65; 95% CI 1.00 to 2.68; p<0.043); the two variables associated with death were pulse therapy with methylprednisolone or cyclophosphamide (PR 2.86; 95% CI 1.59 to 5.14; p<0.018). CONCLUSIONS: Age >50 years and immunosuppression with GC and cyclophosphamide were associated with unfavourable outcomes of COVID-19. Treatment with TNFi may have been protective, perhaps leading to the COVID-19 inflammatory process. BMJ Publishing Group 2021-01-28 /pmc/articles/PMC7844930/ /pubmed/33510041 http://dx.doi.org/10.1136/rmdopen-2020-001461 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Infections
Marques, Claudia Diniz Lopes
Kakehasi, Adriana Maria
Pinheiro, Marcelo Medeiros
Mota, Licia Maria Henrique
Albuquerque, Cleandro Pires
Silva, Carolina Rocha
Santos, Gabriela Porfirio Jardim
Reis-Neto, Edgard Torres
Matos, Pedro
Devide, Guilherme
Dantas, Andrea
Giorgi, Rina Dalva
Omura, Felipe
Marinho, Adriana de Oliveira
Valadares, Lilian David Azevedo
Melo, Ana Karla G
Ribeiro, Francinne Machado
Ferreira, Gilda Aparecida
Santos, Flavia Patricia de Sena
Ribeiro, Sandra Lucia Euzebio
Andrade, Nicole Pamplona Bueno
Yazbek, Michel Alexandre
de Souza, Viviane Angelina
Paiva, Eduardo S
Azevedo, Valderilio Feijo
de Freitas, Ana Beatriz Santos Bacchiega
Provenza, José Roberto
de Toledo, Ricardo Acayaba
Fontenelle, Sheilla
Carneiro, Sueli
Xavier, Ricardo
Pileggi, Gecilmara Cristina Salviato
Reis, Ana Paula Monteiro Gomides
High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19: first results of ReumaCoV Brasil registry
title High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19: first results of ReumaCoV Brasil registry
title_full High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19: first results of ReumaCoV Brasil registry
title_fullStr High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19: first results of ReumaCoV Brasil registry
title_full_unstemmed High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19: first results of ReumaCoV Brasil registry
title_short High levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and COVID-19: first results of ReumaCoV Brasil registry
title_sort high levels of immunosuppression are related to unfavourable outcomes in hospitalised patients with rheumatic diseases and covid-19: first results of reumacov brasil registry
topic Infections
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7844930/
https://www.ncbi.nlm.nih.gov/pubmed/33510041
http://dx.doi.org/10.1136/rmdopen-2020-001461
work_keys_str_mv AT marquesclaudiadinizlopes highlevelsofimmunosuppressionarerelatedtounfavourableoutcomesinhospitalisedpatientswithrheumaticdiseasesandcovid19firstresultsofreumacovbrasilregistry
AT kakehasiadrianamaria highlevelsofimmunosuppressionarerelatedtounfavourableoutcomesinhospitalisedpatientswithrheumaticdiseasesandcovid19firstresultsofreumacovbrasilregistry
AT pinheiromarcelomedeiros highlevelsofimmunosuppressionarerelatedtounfavourableoutcomesinhospitalisedpatientswithrheumaticdiseasesandcovid19firstresultsofreumacovbrasilregistry
AT motaliciamariahenrique highlevelsofimmunosuppressionarerelatedtounfavourableoutcomesinhospitalisedpatientswithrheumaticdiseasesandcovid19firstresultsofreumacovbrasilregistry
AT albuquerquecleandropires highlevelsofimmunosuppressionarerelatedtounfavourableoutcomesinhospitalisedpatientswithrheumaticdiseasesandcovid19firstresultsofreumacovbrasilregistry
AT silvacarolinarocha highlevelsofimmunosuppressionarerelatedtounfavourableoutcomesinhospitalisedpatientswithrheumaticdiseasesandcovid19firstresultsofreumacovbrasilregistry
AT santosgabrielaporfiriojardim highlevelsofimmunosuppressionarerelatedtounfavourableoutcomesinhospitalisedpatientswithrheumaticdiseasesandcovid19firstresultsofreumacovbrasilregistry
AT reisnetoedgardtorres highlevelsofimmunosuppressionarerelatedtounfavourableoutcomesinhospitalisedpatientswithrheumaticdiseasesandcovid19firstresultsofreumacovbrasilregistry
AT matospedro highlevelsofimmunosuppressionarerelatedtounfavourableoutcomesinhospitalisedpatientswithrheumaticdiseasesandcovid19firstresultsofreumacovbrasilregistry
AT devideguilherme highlevelsofimmunosuppressionarerelatedtounfavourableoutcomesinhospitalisedpatientswithrheumaticdiseasesandcovid19firstresultsofreumacovbrasilregistry
AT dantasandrea highlevelsofimmunosuppressionarerelatedtounfavourableoutcomesinhospitalisedpatientswithrheumaticdiseasesandcovid19firstresultsofreumacovbrasilregistry
AT giorgirinadalva highlevelsofimmunosuppressionarerelatedtounfavourableoutcomesinhospitalisedpatientswithrheumaticdiseasesandcovid19firstresultsofreumacovbrasilregistry
AT omurafelipe highlevelsofimmunosuppressionarerelatedtounfavourableoutcomesinhospitalisedpatientswithrheumaticdiseasesandcovid19firstresultsofreumacovbrasilregistry
AT marinhoadrianadeoliveira highlevelsofimmunosuppressionarerelatedtounfavourableoutcomesinhospitalisedpatientswithrheumaticdiseasesandcovid19firstresultsofreumacovbrasilregistry
AT valadaresliliandavidazevedo highlevelsofimmunosuppressionarerelatedtounfavourableoutcomesinhospitalisedpatientswithrheumaticdiseasesandcovid19firstresultsofreumacovbrasilregistry
AT meloanakarlag highlevelsofimmunosuppressionarerelatedtounfavourableoutcomesinhospitalisedpatientswithrheumaticdiseasesandcovid19firstresultsofreumacovbrasilregistry
AT ribeirofrancinnemachado highlevelsofimmunosuppressionarerelatedtounfavourableoutcomesinhospitalisedpatientswithrheumaticdiseasesandcovid19firstresultsofreumacovbrasilregistry
AT ferreiragildaaparecida highlevelsofimmunosuppressionarerelatedtounfavourableoutcomesinhospitalisedpatientswithrheumaticdiseasesandcovid19firstresultsofreumacovbrasilregistry
AT santosflaviapatriciadesena highlevelsofimmunosuppressionarerelatedtounfavourableoutcomesinhospitalisedpatientswithrheumaticdiseasesandcovid19firstresultsofreumacovbrasilregistry
AT ribeirosandraluciaeuzebio highlevelsofimmunosuppressionarerelatedtounfavourableoutcomesinhospitalisedpatientswithrheumaticdiseasesandcovid19firstresultsofreumacovbrasilregistry
AT andradenicolepamplonabueno highlevelsofimmunosuppressionarerelatedtounfavourableoutcomesinhospitalisedpatientswithrheumaticdiseasesandcovid19firstresultsofreumacovbrasilregistry
AT yazbekmichelalexandre highlevelsofimmunosuppressionarerelatedtounfavourableoutcomesinhospitalisedpatientswithrheumaticdiseasesandcovid19firstresultsofreumacovbrasilregistry
AT desouzavivianeangelina highlevelsofimmunosuppressionarerelatedtounfavourableoutcomesinhospitalisedpatientswithrheumaticdiseasesandcovid19firstresultsofreumacovbrasilregistry
AT paivaeduardos highlevelsofimmunosuppressionarerelatedtounfavourableoutcomesinhospitalisedpatientswithrheumaticdiseasesandcovid19firstresultsofreumacovbrasilregistry
AT azevedovalderiliofeijo highlevelsofimmunosuppressionarerelatedtounfavourableoutcomesinhospitalisedpatientswithrheumaticdiseasesandcovid19firstresultsofreumacovbrasilregistry
AT defreitasanabeatrizsantosbacchiega highlevelsofimmunosuppressionarerelatedtounfavourableoutcomesinhospitalisedpatientswithrheumaticdiseasesandcovid19firstresultsofreumacovbrasilregistry
AT provenzajoseroberto highlevelsofimmunosuppressionarerelatedtounfavourableoutcomesinhospitalisedpatientswithrheumaticdiseasesandcovid19firstresultsofreumacovbrasilregistry
AT detoledoricardoacayaba highlevelsofimmunosuppressionarerelatedtounfavourableoutcomesinhospitalisedpatientswithrheumaticdiseasesandcovid19firstresultsofreumacovbrasilregistry
AT fontenellesheilla highlevelsofimmunosuppressionarerelatedtounfavourableoutcomesinhospitalisedpatientswithrheumaticdiseasesandcovid19firstresultsofreumacovbrasilregistry
AT carneirosueli highlevelsofimmunosuppressionarerelatedtounfavourableoutcomesinhospitalisedpatientswithrheumaticdiseasesandcovid19firstresultsofreumacovbrasilregistry
AT xavierricardo highlevelsofimmunosuppressionarerelatedtounfavourableoutcomesinhospitalisedpatientswithrheumaticdiseasesandcovid19firstresultsofreumacovbrasilregistry
AT pileggigecilmaracristinasalviato highlevelsofimmunosuppressionarerelatedtounfavourableoutcomesinhospitalisedpatientswithrheumaticdiseasesandcovid19firstresultsofreumacovbrasilregistry
AT reisanapaulamonteirogomides highlevelsofimmunosuppressionarerelatedtounfavourableoutcomesinhospitalisedpatientswithrheumaticdiseasesandcovid19firstresultsofreumacovbrasilregistry